Mangoceuticals, Inc. (MGRX)
NASDAQ: MGRX · Real-Time Price · USD
0.360
-0.040 (-9.95%)
At close: Apr 28, 2026, 4:00 PM EDT
0.362
+0.002 (0.53%)
After-hours: Apr 28, 2026, 7:58 PM EDT
Mangoceuticals Revenue
In the year 2025, Mangoceuticals had annual revenue of $456.02K, down -25.96%. Mangoceuticals had revenue of $94.36K in the quarter ending December 31, 2025, a decrease of -10.34%.
Revenue (ttm)
$456.02K
Revenue Growth
-25.96%
P/S Ratio
13.60
Revenue / Employee
$152,007
Employees
3
Market Cap
6.11M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 456.02K | -159.85K | -25.96% |
| Dec 31, 2024 | 615.87K | -115.62K | -15.81% |
| Dec 31, 2023 | 731.49K | 722.55K | 8,083.16% |
| Dec 31, 2022 | 8.94K | - | - |
| Dec 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Well | 249.33M |
| Forian | 30.26M |
| DarioHealth | 22.36M |
| VSee Health | 14.62M |
| Healthcare Triangle | 13.89M |
| Zhongchao | 11.37M |
| Mobile-health Network Solutions | 7.32M |
| OneMedNet | 1.36M |
MGRX News
- 5 weeks ago - Mangoceuticals Stock Doubles After Texas Lawsuit - Benzinga
- 6 weeks ago - Mangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc. - GlobeNewsWire
- 7 weeks ago - Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds - GlobeNewsWire
- 2 months ago - Mangoceuticals' Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled Government Study - GlobeNewsWire
- 2 months ago - Mangoceuticals Stock Skyrockets 50% Friday: What's Driving The Rally? - Benzinga
- 2 months ago - Mangoceuticals Stock Surges On Early Success Of Subscription TRT Model - Benzinga
- 2 months ago - MangoRx Experiences Initial Success with Newly Launched $99/month All-Inclusive Injectable Testosterone Replacement Therapy (TRT) Treatment Program - GlobeNewsWire
- 4 months ago - Mangoceuticals, Inc. Announces Closing of $2.5 Million Registered Direct and Private Placements - GlobeNewsWire